“There are 4 types of Dengue strains and all of those were transmitted to the Dengvaxia vaccine recipients “, says a pediatric doctor from St. Lukes Hospital Bonifacio Global City in the Philippines.
The pathophysiology of the vaccine clearly implies that ‘Dengvaxia’ isn’t fit for public consumption.
The statistics of Dengue cases in the Philippines may have compelled WHO, Sanofi Pasteur and the Philppine government through its Department of Health to conduct mass testing of the vaccine mostly to public school students.
What was supposed to cure Dengue outbreaks in targeted communities have simply failed to deliver and did exactly unforthcoming- Dengvaxia gave 4 strains of Dengue viruses to the vaccine receptors as if they already had the virus for 4 times already.
As a result, the vaccine will aggravate the respondent’s condition once they get infected by the Dengue-causing mosquito.
What can ‘Dengvaxia’ recipients do? “NOTHING. Unfortunately, they need to be careful not to have the Dengue virus in their system since they cannot afford to have the consequences from the vaccine”, added the source from St. Luke’s BGC.
It was believed that Sanofi Pasteur conducted a clinical trial in the Philippines through the Department of Health with then DOH Secretary Janet Garin‘s supervision.
Clinical trials have different phases and Dengvaxia was said to be on Phase 3. It
was administered to unintentional victims who basically had zero-knowledge of what could arise after testing the vaccine on them.
The Philippine government advises the public not to panic despite the commotion that is already circling the issue.
To understand the phases of clinical testing, watch this:
Download PULSE VIRUS TRACKER for disease surveillance purposes @ www.penchat.net